

## NEWS RELEASE

FOR IMMEDIATE RELEASE



## ICPO Foundation participates in the 7<sup>th</sup> Theranostics World Congress (TWC) in Santiago de Chile from 22<sup>nd</sup> to 24<sup>th</sup> of March 2024

On the congress the International Centers for Precision Oncology will present the ICPO Academy for Theranostics and host two sessions about TME Diagnostics and TME Therapeutics as well as a joint Patient and Experts session together with the Oncidium Foundation.

February 5, 2024 – Wiesbaden, Germany – The TWC is a global congress that unites leading experts in the field of Theranostics from various parts of the world and will take place at the W Hotel in Santiago de Chile from 22<sup>nd</sup> to 24<sup>th</sup> of March 2024. Its objective is to serve as a platform for researchers, clinicians, industry professionals, and students to exchange knowledge, as well as to explore and discuss the latest advancements in the dynamic field of Theranostics. In collaboration with the Oncidium Foundation, the ICPO Foundation will host a joint Patient and Expert discussion session. Additionally, ICPO aims to spotlight two sessions focusing on TME Diagnostics and TME Therapeutics on March 23, 2024. Moreover, there will be a one-day pre-conference event on March 21, 2024. ICPO Foundation will introduce the ICPO Academy for Theranostics to the audience. To enhance this experience, The ICPO Foundation invites all attendees to visit its booth at C04, fostering community expansion and providing an opportunity to engage with numerous partners.

The 7<sup>th</sup> Theranostics World Congress program will cover a wide range of topics with dedicated sessions on prostate cancer, neuroendocrine tumors, targeting tumor microenvironment, new radioisotopes and their production, novel radiochemistry and chelators, combination therapies, patient access, and many others. Directly following the opening ceremony and lecture on March 22, 2024 ICPO Foundation and Oncidium Foundation will organize a Patient and Experts session with the title: "Radiotheranostics Global Access: Discussion with Patients and Experts – Building hope: navigating through the challenges and barriers to treatment".

ICPO Foundation is pleased to have gained the following experts for the session VII with the title "**TME Diagnostics**": Pieter van der Veken (University of Antwerp, Belgium) DRUGLIKE, 18F-LABELED PET TRACERS TARGETING FIBROBLAST ACTIVATION PROTEIN (FAP), Frederik Giesel (Heinrich Heine University Düsseldorf, Germany) – virtual OVERVIEW OF TODAY'S CLINICAL APPLICATIONS AND PERSPECTIVES, Sherly Mosessian (Sofie Bioscience, USA) & Paul Evans (GE, USA) FAPI – ADVANCEMENTS IN DIAGNOSTICS and Tadashi Watabe (Osaka University, Japan) – FAPI DIAGNOSTICS – CRITICAL VIEW ON CLINICAL DEVELOPMENT.

For the session VIII with the title "**TME Theranostics**" the following program is planned: Richard P. Baum (Curanosticum & ICPO, Germany) CLINICAL APPLICATIONS AND PERSPECTIVES OF 3BP-3940, Marcel Martin (University Mainz, Germany) FAPI-DIMERS-CHEMISTRY AND PRECLINICAL EVALUATION, Sanjana Ballal (AIIMS, New Delhi, India) ASSESSING THE LONG-TERM IMPACT OF FAP DIMER THERAPY IN CANCER TREATMENT, John Babich (Ratio Therapeutics, USA) NEXT GENERATION 64CU- AND 225AC-LABELLED RADIOLIGANDS FOR FAP-TARGETED THERAPY, Jacqueline Mock (Philogen, USA) – virtual NOVEL FAP-TARGETING SMALL MOLECULE RADIO-CONJUGATES WITH HIGH AND PROLONGED

## NEWS RELEASE



### FOR IMMEDIATE RELEASE

TUMOUR UPTAKE, Jingjing Zhang (University of Singapore, Singapore) RADIOTHERANOSTICS WITH DUAL TARGETING PROBE 68GA-/18F-/177LU-FAPI-RGD IN DIVERSE SOLID TUMORS.

The panel discussions will be led by Frank Rösch.

During the pre-conference on March 21, 2024, Odile Jaume, CEO of the ICPO Foundation, and Prof. Richard P. Baum, the President of the ICPO Academy for Theranostics, will present the online education program together with the pillar leaders and experts Elcin Zan, Thomas Beyer, Frank Rösch and Josh Mailman.

The ICPO Academy for Theranostics offers an extensive educational program developed by the ICPO Foundation. This online program covers more than 50 hours of content and is backed by a global community of over 30 experts and leaders active in medicine, science, technology and patient care. The content is accessible in multiple languages. The curriculum has been developed under the guidance of its President, Prof. Richard P. Baum, world leader and pioneer in Radiomolecular Precision Oncology, together with prominent Pillar Leaders, international experts in their respective field, namely Prof. Vikas Prasad, Prof. Thomas Beyer, Prof. Frank Rösch, Linda Gardner and Josh Mailman. Due to their extensive accumulated knowledge and experience, along with their personal dedication, they have curated an exclusive and comprehensive online educational program. More information can be found on the website: [www.theranostics.adacemy](http://www.theranostics.adacemy)

Please find all general information about the TWC here: [7th Theranostics World Congress \(theranostics-world-congress.org\)](https://www.theranostics-world-congress.org) and get an overview of the program: [TWC'24 Draft1 Scientific Program without-Industry 24-02-01.pdf \(theranostics-world-congress.org\)](https://www.theranostics-world-congress.org/TWC24_Draft1_Scientific_Program_without-Industry_24-02-01.pdf)

### About ICPO Foundation

The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation is helping to build momentum to scale global patient access to Radiomolecular Precision Oncology to support this shift. To scale patient access, the ICPO Foundation aims to develop an international network of physical diagnostic and therapeutic Centers for Precision Oncology organized in a Social Franchise model based on shared know-how, certified education with so called Academy, and design and process standardization that enables best clinical practice globally. Furthermore, it is the ICPO Foundation's objective to empower its Centers by embedding them in a highly inclusive Community that spearheads its model and lives up to the Precision Oncology promise, by making it available to all patients in need, irrespective of country or social status.

Learn more about the ICPO Foundation at [www.icpo.foundation](http://www.icpo.foundation) and about the ICPO Academy for Theranostics at [www.theranostics.academy](http://www.theranostics.academy)

# NEWS RELEASE

FOR IMMEDIATE RELEASE



## Media contact ICPO Foundation

Susanne Simon

Head of Communication & Community

Email: [susanne.simon@icpo.foundation](mailto:susanne.simon@icpo.foundation)

Phone: + 49 172 8666093

[www.icpo.foundation](http://www.icpo.foundation)